Formulation strategies for Poorly Soluble Molecules –
Pharmaceutics & Biopharmaceutics Considerations
Listen to Quotient’s Vice President of Drug Development Sciences, Dr Sarah Stevens and Executive Director of Product Development, Dr Asma Patel as they share expert insight and case studies on formulation and solubility challenges and discuss the best strategies and technologies for advancing poorly soluble molecules, to deliver success.
Leveraging Taste Masking, Modelling & Simulation, Clinical PK and Taste Assessment Studies to Achieve Program Success
Listen to Quotient’s Executive Director of Pediatric Development, Nazim Kanji and Research Fellow, Ashley Willson as they review current industry standards and future expectations for pediatric drug development, along with EU and US regulatory landscapes. They will cover formulation and taste masking strategies, taste assessment studies, fit-for-purpose manufacturing of clinical trial supplies and leveraging physiologically based pharmacokinetic modelling and simulation, to guide dose selection and product design.
News– “Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization” Read More
Blog- “Getting Your Product to the Right Patient at the Right Time: Flexible, On-Demand Product Manufacturing and Clinical Trial Supplies” – Read More
Blog– “Effective Taste Masking Strategies and Techniques” – Read More
Special Feature Article in Drug Development & Delivery– “Improving Bioavailability & Solubility: Each Molecule Is Unique” – Read More
Blog– “Virtually Achieving Quality Assurance Audits” – Read More
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.